Fig. 7From: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicityIncapacity of bispecific antibody AP203 to induce the production of proinflammatory cytokines. PBMCs from healthy donors were treated with isotype antibody (negative control), OKT3 (positive control), TGN1412 (positive control), and soluble A or immobilized B bispecific antibody AP230 for 24 h. The levels of the secreted cytokines i IL-1β, IL-2, IL-6, IL-8, IL-10, IL-13, IL-17A, TNF-α, and IFN-γ in the culture supernatant were measured by ProcartaPlex Immunoassays. Even with high-dose AP230 treatment, inflammatory cytokines were not significantly elevated, indicating the safety of AP203Back to article page